Viewing Study NCT02775903

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 7:34 PM
Ignite Modification Date: 2026-02-27 @ 10:38 AM
Study NCT ID: NCT02775903
Status: COMPLETED
Last Update Posted: 2023-02-28
First Post: 2016-05-16
Is Gene Therapy: True
Has Adverse Events: True
Brief Title: An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML)
Sponsor: Celgene
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Leukemia, Myeloid, Acute View
None Myelodysplastic Syndromes View
Keywords:

Keywords

Keyword Brief Keyword Text View
None MEDI4736 View
None Durvalumab View
None Myelodysplastic Syndromes View
None Acute Myeloid Leukemia View
None Hematopoietic Stem Cell Transplantation View
None Azacitidine View
None Safety View
None Efficacy View
None PD-L1 View